Dr. Lipson on the Current Treatment Landscape of Basal Cell Carcinoma

Video

Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.

Evan J. Lipson, MD, associate professor of oncology at Johns Hopkins University, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.

Treatment for patients with locally advanced, unresectable, or metastatic basal cell carcinoma falls into 2 categories, Lipson says. The first category features hedgehog inhibitors, which include 2 agents currently approved by the FDA: sonidegib (Odomzo) and vismodegib (Erivedge), Lipson explains. These agents are standard-of-care therapy in the frontline setting for patients with advanced basal cell carcinoma, Lipson says.

The second category is comprised of anti–PD-1 therapy, which includes cemiplimab (Libtayo), another FDA-approved agent for the treatment of patients with advanced basal cell carcinoma Lipson continues. Overall, targeted agents and immunotherapy are available and approved in the treatment of advanced basal cell carcinoma, Lipson concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Related Content
Eric S. Christenson, MD, assistant professor, oncology, Johns Hopkins Medicine

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024
Article
Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC

Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC

October 17th 2022
Podcast
Benjamin P. Levy, MD

Segmenting the Utility of ADCs in NSCLC: How These Agents Are Affecting Second-Line Standards

April 3rd 2024
Article
FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC

FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC

August 25th 2022
Podcast
Benjamin Philip Levy, MD, associate professor, oncology, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital

Tackling All Questions ADC: How These Agents Are Joining a Treatment Revolution in NSCLC

February 26th 2024
Article
Benjamin Levy, MD

Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization

February 7th 2024
Article